Cas No.: | 2569009-58-9 |
Chemical Name: | PF-9363 |
Synonyms: | Schembl22802418;PF-9363 |
SMILES: | S(C1C(=CC=CC=1OC)OC)(NC1C2C(=CC(CN3C=CC=N3)=CC=2ON=1)OC)(=O)=O |
Formula: | C20H20N4O6S |
M.Wt: | 444.461003303528 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Publication: | [1]. Shikhar S, et al. First-in-class KAT6A/KAT6B Inhibitor CTx-648 (PF-9363) Demonstrates Potent Anti-tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation [2]. WO2020254946 |
Description: | PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer[1][2]. |
In Vivo: | PF-9363 shows strong anti-tumor activity in patient-derived xenograft models[1]. |
In Vitro: | PF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker[1]. PF-9363 leads to down regulation of a specific set of genes involved in ESR1 pathway, cell cycle and stem cell pathways. PF-9363 shows that the IC50 values for ZR75-1 and T47D are 0.3 nM and 0.9 nM[1]. Western Blot Analysis[1] Cell Line: ZR75-1, T47D and MCF7 cells Concentration: 0~1 μM Incubation Time: 1 day Result: Down-regulated the expression of H3K23Ac biomarker. |